021-51111890
购物车（）
sales@molnova.cn
Acetyl-(Ala11·15)-Endothelin-1 (6-21)
CAS No. 143113-45-5
Acetyl-(Ala11·15)-Endothelin-1 (6-21) ( ——— )
产品货号. M40168 CAS No. 143113-45-5
BQ-3020 是一种内皮素受体 (endothelin receptor) (ETBreceptor) 激动剂，取代[125I]ET-1 与猪小脑 ETB 受体结合，IC50 值为 0.2 nM。BQ-3020 引起兔肺动脉血管收缩和猪膀胱颈松弛，可用于心血管疾病研究。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 25MG | 获取报价 | 有现货 |
|
| 50MG | 获取报价 | 有现货 |
|
| 100MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Acetyl-(Ala11·15)-Endothelin-1 (6-21)
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述BQ-3020 是一种内皮素受体 (endothelin receptor) (ETBreceptor) 激动剂，取代[125I]ET-1 与猪小脑 ETB 受体结合，IC50 值为 0.2 nM。BQ-3020 引起兔肺动脉血管收缩和猪膀胱颈松弛，可用于心血管疾病研究。
-
产品描述BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research12.
-
体外实验BQ-3020 (3 mg/kg 皮下注射, 单次给药) 可使癌痛小鼠模型在注射后 3 小时内的癌痛减轻约 50%。Animal Model:Cancer pain mouse model Dosage:3 mg/kg Administration:Injected subcutaneously at the site of the greatest tumor development Result:Attenuated cancer pain by approximately 50% up to 3 h post-injection compared to PBS-vehicle and contralateral injection
-
体内实验BQ-3020（0.01–300 nM，7分钟）对 PhE 预收缩的尿路上皮剥离组织产生浓度依赖性松弛。BQ-3020 (0.01–200 nM，20 min) 通过抑制 ETB 受体引起兔肺动脉剂量依赖性血管收缩，其 EC50 值为 0.57 nM。
-
同义词———
-
通路Others
-
靶点Other Targets
-
受体ETB: 0.2 nM (IC50)
-
研究领域———
-
适应症———
化学信息
-
CAS Number143113-45-5
-
分子量1989.36
-
分子式C96H139N20O24S
-
纯度>98% (HPLC)
-
溶解度———
-
SMILES———
-
化学全称———
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
L-BMAA hydrochloride
β-N-methylamino-L-alanine hydrochloride (BMAA hydrochloride) 是一种蓝细菌产生的神经毒素，可能导致肌萎缩性侧索硬化症 (ALS) 以及其他可能的神经退行性疾病。
-
pep2-SVKI
Inhibitor peptide corresponding to last 10 amino acids of the C-terminus of the GluA2 AMPA receptor subunit. Disrupts binding of GluA2 (at the C-terminal PDZ site) with glutamate receptor interacting protein (GRIP), AMPA receptor binding protein (ABP) and protein interacting with C kinase (PICK1). Increases amplitude of AMPA receptor-mediated currents and blocks long-term depression (LTD).
-
3,4,5-Tricaffeoylqui...
3,4,5-Tricaffeoylquinic acid may attenuate the TNF-α±- and LPS-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor 4 expression-mediated activation of the Akt, ERK and NF-κB pathways, it may exert an inhibitory effect against the pro-inflammatory mediator-induced skin disease.
